Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen

Murakami, Kazunari; Takahashi, Ryoki; Ono, Masami; Watanabe, Koichiro; Kodama, Masaaki; Abe, Daijiro; Kimura, Moto; Fujioka, Toshio

doi:10.1007/s00535-011-0414-x

Cited by 14 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…H. hepaticus infection has been suggested to accelerate the progression of HBV and HCV infection. (31) The present study showed that the rate of positive detection of anti-H. …”

Section: Discussionsupporting

confidence: 50%

See 1 more Smart Citation

Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue

Yang¹,

Ji²,

Zhang³

et al. 2013

smedj

View full text Add to dashboard Cite

INTRODUCTION Helicobacter (H.) hepaticus infection causes chronic active hepatitis and induces hepatocellular tumours in A/JCr mice, but evidence of this in humans is scarce. This study aimed to demonstrate the correlation between H. hepaticus and human primary hepatocellular carcinoma (HCC). MeThODsThe sera of 50 patients with primary HCC were tested for the presence of anti-H. pylori and anti-H. hepaticus immunoglobulin G (IgG) antibodies. The liver tissues of patients who tested positive for serum antibody were analysed for H. hepaticus-specific 16S rRNA, H. hepaticus cdtB, H. pylori cagA, H. pylori vacA and H. pylori ureC genes using polymerase chain reaction. ResUlTsAfter the anti-H. pylori antibodies in the serum samples were absorbed by H. pylori antigen, the anti-H. hepaticus IgG serum antibody detection rate was 50.0% in patients with primary HCC. This was significantly higher (p < 0.001) than the detection rate in the benign liver tumour (7.7%) and normal liver tissue (6.3%) groups. Of the 25 primary HCC samples that tested positive for anti-H. hepaticus IgG serum antibody, the H. hepaticus-specific 16S rRNA gene was detected in nine (36.0%) samples. Sequencing showed that the polymerase chain reaction-amplified product exhibited 95.5%-100% homology to the H. hepaticus-specific 16S rRNA gene. Among these nine primary HCC tissue samples, the H. hepaticus cdtB gene was detected in four (44.4%) samples, while no such expression was observed in the benign liver tumour or normal liver tissue groups. CONClUsIONThe present study identified the presence of H. hepaticus infection in patients with primary HCC using serological and molecular biological detection, suggesting that H. hepaticus infection may be involved in the progression of HCC.

show abstract

“…H. hepaticus infection has been suggested to accelerate the progression of HBV and HCV infection. (31) The present study showed that the rate of positive detection of anti-H. …”

Section: Discussionsupporting

confidence: 50%

“…(31) The highest H. hepaticus antigen level was found in the sera of patients with hepatic cirrhosis, followed by that in the sera of patients with hepatitis complicated by HBV or HCV infection. These groups had H. hepaticus antigen levels that were significantly higher than those in patients with common liver diseases.…”

Section: Discussionmentioning

confidence: 95%

Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue

Yang¹,

Ji²,

Zhang³

et al. 2013

smedj

View full text Add to dashboard Cite

show abstract

“…Subsequent procedures were performed using an ELISA kit according to the manufacturer's instructions. 22 After 20 minutes at room temperature, a slat was taken from the sealed foil for creation of sample and standard holes. Sample holes were added to test 10 µL samples first, after which the diluent sample volume added was 40 µL.…”

Section: Pathologic Observations On Elisamentioning

confidence: 99%

Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin

Zhang¹,

Lv²,

Li³

et al. 2013

IJN

View full text Add to dashboard Cite

Background:The purpose of this work was to develop nanostructured lipid carriers (NLCs) loaded simultaneously with oleanolic acid and gentiopicrin. Methods: An aqueous dispersion of NLCs was prepared successfully using a film-ultrasonic method, with glycerin monostearate as the solid lipid and oleic acid as the liquid lipid. Poloxamer 188 was used as the surfactant. A central composite design was used to optimize the technologic parameters. The characteristics of the NLCs were then investigated. Results: The encapsulation efficiency was 48.34% ± 2.76%, drug loading was 8.06% ± 0.42%, particle size was 111.0 ± 1.56 nm, polydispersity index was 0.287 ± 0.01, and zeta potential was −23.8 ± 0.36 mV for the optimized NLCs. The other physicochemical properties were characterized by transmission electron microscopy and differential scanning calorimetry. Drug release followed first-order kinetics and release studies confirmed that oleanolic acid and gentiopicrin fitted a sustained-release model. Compared with NLCs loaded with oleanolic acid or gentiopicrin alone, NLCs loaded with both oleanolic acid and gentiopicrin produced drug concentrations which persisted for a significantly longer time in plasma, with a linear decrement following second-order kinetics. Aspartate and alanine aminotransferase levels were significantly lower on exposure to NLCs loaded with both oleanolic acid and gentiopicrin than in negative controls. Conclusion:The results of this study confirm that oleanolic acid and gentiopicrin can be loaded simultaneously into NLCs. Compared with oleanolic acid and gentiopicrin loaded alone, sustained release and protective effects against hepatic injury were observed using NLCs loaded with both oleanolic acid and gentiopicrin.

show abstract

“…A meta-analysis based on a systematic review of 18 studies published between 1998 and 2011 revealed a significantly higher pooled infection rate for H. pylori and Helicobacter hepaticus in patients with lithiasis [5]. In another study from Japan, Murakami et al [6] found increased concentrations of anti-H. hepaticus antibodies in the sera of patients with liver disease compared with those suffering from other groups using ELISA and western blot with the new monoclonal antibody HR II-51. The authors concluded that H. hepaticus infection might play a role in the development of liver disease, especially in HBV and/or HCV-infected patients.…”

Section: Hepatobiliary Diseasementioning

confidence: 99%

Helicobacter spp. Other than H. pylori

Rossi

Hänninen

2012

Helicobacter

View full text Add to dashboard Cite

Significant advances have been made over the last 12 months in the understanding of the biology of non-H. pylori Helicobacter species (NHPH). Several studies have investigated the association between NHPH and human disease, including Crohn's disease, lithiasis, liver disease, coronary disease, gastritis, and pyoderma gangrenosum-like ulcers. Novel Helicobacter taxa were identified in new vertebrate hosts, and new methodologies in the fields of identification of Helicobacter spp. and evaluation of antibiotic resistance were described. The genome of the first human-derived gastric NHPH strain (Helicobacter bizzozeronii CIII-1) was sequenced, and several studies elucidated functions of different genes in NHPH. A number of important investigations regarding pathogenesis and immunopathobiology of NHPH infections have been published including the description of a new urease in Helicobacter mustelae. Finally, the effects of the gut microbiota and probiotics on NHPH infections were investigated.

show abstract

Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen

Abstract: H. hepaticus infection might play a role in the development of liver diseases; in particular, it might increase the risk of the development of HBV- and/or HCV-infected liver diseases.

Cited by 14 publications

References 17 publications

Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue

Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue

Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin

Helicobacter spp. Other than H. pylori

Contact Info

Product

Resources

About